<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>PESI Score for Pulmonary Embolism</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->11/17/2012</div></div><div class="card__content"><h1 id="pesi-score-for-pulmonary-embolism">PESI Score for Pulmonary Embolism</h1>
<h2 id="pulmonary-embolism-severity-index-pesi-score-calculation">Pulmonary Embolism Severity Index (PESI) score calculation</h2>
<table>
<thead>
<tr>
<th>Finding</th>
<th>Points</th>
</tr>
</thead>
<tbody><tr>
<td>Age</td>
<td>+1 per year</td>
</tr>
<tr>
<td>Male gender</td>
<td>+10</td>
</tr>
<tr>
<td>Cancer (history of or active)</td>
<td>+30</td>
</tr>
<tr>
<td>Heart failure</td>
<td>+10</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>+10</td>
</tr>
<tr>
<td>Pulse &ge;110 beats per min</td>
<td>+20</td>
</tr>
<tr>
<td>SBP &lt;100 mmHg</td>
<td>+30</td>
</tr>
<tr>
<td>RR &ge;30 breaths per min</td>
<td>+20</td>
</tr>
<tr>
<td>Temperature &lt;36C</td>
<td>+20</td>
</tr>
<tr>
<td>Altered mental status</td>
<td>+60</td>
</tr>
<tr>
<td>Arterial oxygen saturation &lt;90%</td>
<td>+20</td>
</tr>
</tbody></table>
<table>
<thead>
<tr>
<th>Class</th>
<th align="right">Point Total</th>
</tr>
</thead>
<tbody><tr>
<td>I</td>
<td align="right">&lt;66</td>
</tr>
<tr>
<td>II</td>
<td align="right">66-85</td>
</tr>
<tr>
<td>III</td>
<td align="right">86-105</td>
</tr>
<tr>
<td>IV</td>
<td align="right">106-125</td>
</tr>
<tr>
<td>V</td>
<td align="right">&gt;125</td>
</tr>
</tbody></table>
<h2 id="outpatient-treatment-of-pulmonary-embolism-otpe-trial">Outpatient Treatment of Pulmonary Embolism (OTPE) trial</h2>
<h3 id="study-design">Study design</h3>
<p>Randomized, prospective, non-inferiority clinical trial of 19 ED’s (n = 344 patients) in Switzerland, France, Belgium, and USA looking at morbidity/mortality of PESI class I and II patients</p>
<h3 id="exclusion-criteria-from-study">Exclusion criteria from study</h3>
<ul>
<li>Arterial hypoxemia (O2 saturation &lt;90% on room air, or paO2 &lt;60 mmHg)</li>
<li>SBP &lt;100 mmHg</li>
<li>Chest pain necessitating parental opioids</li>
<li>Active bleeding</li>
<li>High risk of bleeding defined as: CVA during preceding 10 days, GI bleeding in preceding 14 days, or platelets &lt;75K </li>
<li>Severe renal failure (CrCl &lt;30 mL per min)</li>
<li>Extreme obesity (body mass &gt;150 kg)</li>
<li>History of heparin-induced thrombocytopenia or allergy to heparins</li>
<li>Therapeutic oral anticoagulation at time of PE diagnosis (INR &ge;2)</li>
<li>Any barriers to treatment adherence (current EtOH abuse, illicit drug use, psychosis, dementia, homelessness)</li>
<li>Pregnancy</li>
<li>Imprisonment</li>
<li>Diagnosis of PE &gt;23 hrs before time of screening</li>
</ul>
<h3 id="results">Results</h3>
<ul>
<li>Complication rates were calculated based on whether PE was managed as an outpatient or inpatient.</li>
</ul>
<table>
<thead>
<tr>
<th>Complications</th>
<th align="right">Outpatient</th>
<th align="right">Inpatient</th>
</tr>
</thead>
<tbody><tr>
<td>Major bleeding at &le;14 days</td>
<td align="right">1.2% (2/171)</td>
<td align="right">0% (0/168)</td>
</tr>
<tr>
<td>Major bleeding at &le;90 days</td>
<td align="right">1.8% (1/171)</td>
<td align="right">0% (0/168)</td>
</tr>
<tr>
<td>Recurrent venous thromboembolism at &le;90 days</td>
<td align="right">0.6% (1/171)</td>
<td align="right">0% (0/168)</td>
</tr>
<tr>
<td>Death at &le;90 days</td>
<td align="right">0.6% (1/171)</td>
<td align="right">0.6% (1/168)</td>
</tr>
</tbody></table>
<h3 id="outpatient-treatment">Outpatient treatment</h3>
<p><span class="drug">Enoxaparin</span> 1 mg/kg SQ BID to bridge into PO <span class="drug">warfarin</span> (target INR=2)</p>
<h2 id="conclusion">Conclusion</h2>
<p>PE patients with PESI class I or II seem safe to manage as outpatients.</p>
<ul>
<li>Be aware of exclusion criteria from study</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li>Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N&#39;gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. <em>Lancet</em>. 2011 Jul 2;378(9785):41-8. doi: 10.1016/S0140-6736(11)60824-6.  [<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=21703676">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"pesi","title":"PESI Score for Pulmonary Embolism","authors":["Michelle Lin, MD"],"categories":[{"slug":"pulmonology","name":"Pulmonology"},{"slug":"critical-care","name":"Critical Care"}],"created":"2012/11/17","updated":null,"body":"\n# PESI Score for Pulmonary Embolism\n\n## Pulmonary Embolism Severity Index (PESI) score calculation\n\n| Finding                            | Points      |\n| ---------------------------------- | ----------- |\n| Age                                | +1 per year |\n| Male gender                        | +10         |\n| Cancer (history of or active)      | +30         |\n| Heart failure                      | +10         |\n| Chronic lung disease               | +10         |\n| Pulse \u0026ge;110 beats per min        | +20         |\n| SBP \u0026lt;100 mmHg                   | +30         |\n| RR \u0026ge;30 breaths per min          | +20         |\n| Temperature \u0026lt;36C                | +20         |\n| Altered mental status              | +60         |\n| Arterial oxygen saturation \u0026lt;90% | +20         |\n\n| Class | Point Total |\n| ----- | ----------: |\n| I     |      \u0026lt;66 |\n| II    |       66-85 |\n| III   |      86-105 |\n| IV    |     106-125 |\n| V     |     \u0026gt;125 |\n\n## Outpatient Treatment of Pulmonary Embolism (OTPE) trial\n\n### Study design\n\nRandomized, prospective, non-inferiority clinical trial of 19 ED’s (n = 344 patients) in Switzerland, France, Belgium, and USA looking at morbidity/mortality of PESI class I and II patients\n\n### Exclusion criteria from study\n\n- Arterial hypoxemia (O2 saturation \u0026lt;90% on room air, or paO2 \u0026lt;60 mmHg)\n- SBP \u0026lt;100 mmHg\n- Chest pain necessitating parental opioids\n- Active bleeding\n- High risk of bleeding defined as: CVA during preceding 10 days, GI bleeding in preceding 14 days, or platelets \u0026lt;75K \n- Severe renal failure (CrCl \u0026lt;30 mL per min)\n- Extreme obesity (body mass \u003e150 kg)\n- History of heparin-induced thrombocytopenia or allergy to heparins\n- Therapeutic oral anticoagulation at time of PE diagnosis (INR \u0026ge;2)\n- Any barriers to treatment adherence (current EtOH abuse, illicit drug use, psychosis, dementia, homelessness)\n- Pregnancy\n- Imprisonment\n- Diagnosis of PE \u0026gt;23 hrs before time of screening\n\n### Results\n\n- Complication rates were calculated based on whether PE was managed as an outpatient or inpatient.\n\n| Complications                                   |   Outpatient |    Inpatient |\n| ----------------------------------------------- | -----------: | -----------: |\n| Major bleeding at \u0026le;14 days                   | 1.2% (2/171) |   0% (0/168) |\n| Major bleeding at \u0026le;90 days                   | 1.8% (1/171) |   0% (0/168) |\n| Recurrent venous thromboembolism at \u0026le;90 days | 0.6% (1/171) |   0% (0/168) |\n| Death at \u0026le;90 days                            | 0.6% (1/171) | 0.6% (1/168) |\n\n### Outpatient treatment \n\n\u003cspan class=\"drug\"\u003eEnoxaparin\u003c/span\u003e 1 mg/kg SQ BID to bridge into PO \u003cspan class=\"drug\"\u003ewarfarin\u003c/span\u003e (target INR=2)\n\n## Conclusion\n\nPE patients with PESI class I or II seem safe to manage as outpatients.\n\n- Be aware of exclusion criteria from study\n\n## References\n\n- Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M, Renaud B, Verhamme P, Stone RA, Legall C, Sanchez O, Pugh NA, N'gako A, Cornuz J, Hugli O, Beer HJ, Perrier A, Fine MJ, Yealy DM. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. _Lancet_. 2011 Jul 2;378(9785):41-8. doi: 10.1016/S0140-6736(11)60824-6.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=21703676)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"pesi"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>